About us > Aditya Bardia, MD, MPH, FASCO

Aditya Bardia, MD, MPH, FASCO

Professor, Department of Medicine, Division of Hematology/Oncology; Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center

Aditya Bardia

Highlights

  • Speaker, Updates from the 2026 San Antonio Breast Cancer Symposium
  • Program director of breast medical oncology
  • Led the development of sacituzumab govitecan (Trodelvy),
general_content

Dr. Bardia is known for his clinical and translational research in cancer treatments, particularly antibody-drug conjugates (ADCs), which combine targeted therapy with chemotherapy. He led the development of sacituzumab govitecan (Trodelvy), the first ADC approved for people with metastatic triple-negative breast cancer. He also guided the development of other ADCs, including trastuzumab deruxtecan (Enhertu) and datapotamab deruxtecan (Datroway).

Dr. Bardia also led the clinical development of elacestrant (Orserdu), the first oral selective estrogen receptor degrader (SERD) approved for people with hormone receptor-positive, HER2-negative metastatic breast cancer. Through collaboration with various labs, he has identified the roles of ESR1 mutations in resistance to hormonal therapy, RB1 mutations in resistance to CDK 4/6 inhibitors, and TOP1 mutations in resistance to ADCs.

Beyond his research, Dr. Bardia is highly regarded among peers as a mentor and advocate for academic trainees and junior faculty members. His honors include the Outstanding Research Award from Mayo Clinic, the Young Investigator Award from the American Society of Clinical Oncology, the Distinguished Researcher Award from the Massachusetts Society of Clinical Oncology, and the Douglas Family Foundation Prize for Excellence in Oncology Research.